Publikationer pr. år
Publikationer pr. år
Theresa Junker, Louise Duus, Benjamin S B Rasmussen, Nessn Azawi, Lars Lund, Ole Graumann, Birgitte Nørgaard
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review
BACKGROUND: Despite the fact that nephron-sparing treatment is considered preferable from a surgical perspective patients' quality of life (QoL) following different types of nephron-sparing treatments remains unclear.
PURPOSE: To investigate the quality of life and complications after nephron-sparing treatment of renal cell carcinomas of stage T1.
MATERIALS AND METHODS: A systematic search of six databases was carried out. We included studies that reported the quality of life and complications in patients aged 18 years or older following nephron-sparing treatment of renal cell carcinoma stage T1. The quality assessment was performed using the Critical Appraisal Skills Programme (CASP) checklist for cohort studies and the CASP Randomized Controlled Trial Checklist. Data were analyzed using a narrative approach.
RESULTS: Eight studies were included, six of which investigated QoL after partial nephrectomy and two after ablation therapies. Seven studies reported complications. Three studies reported higher QoL scores after partial nephrectomy compared to radical nephrectomy. Two studies showed that QoL increased or returned to baseline levels up to 12 months following partial nephrectomy. One study reported a gradual increase in QoL after radiofrequency ablation, and one study reported that all patients recovered to baseline QoL following cryoablation. Across studies, we found a complication rate up to 20% after partial nephrectomy and up to 12.5% after ablation therapy.
CONCLUSIONS: The results of this systematic review suggest that nephron-sparing treatment appears to be superior or comparable to other treatment alternatives with regard to QoL outcomes. Additionally, based on the studies included in this review, partial nephrectomy appears to have a higher complication rate compared with ablation therapies.
SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42020155594.
|Status||Udgivet - 4. jan. 2022|
Publikation: Afhandling › Ph.d.-afhandling